E-cadherin与胃癌关系的研究进展
|
摘要
胃癌晚期患者治疗失败和死亡的主要原因是细胞浸润与转移。胃癌细胞的浸润、转移机制是多因素相互作用的复杂结果,探讨其机制并针对其相关标志物寻找治疗靶点,是临床医生面临的巨大挑战。上皮性钙黏蛋白(E-cadherin)可维持上皮细胞间的极性及细胞间的黏附,其表达的减少/缺失可诱导上皮-间充质转化(EMT),在胃癌的进展过程中起着关键作用。文章总结了E-cadherin的功能及其相关的分子机制与胃癌的关系,专注于其在胃癌诊断、预后和治疗中的应用,并对E-cadherin的失活机制进行综述,以便为胃癌的诊断开辟新的途径。
引文
[1]Karimi P,Islami F,Anandasabapathy S,et al.Gastric cancer:descriptive epidemiology,risk factors,screening,and prevention[J].Cancer Epidemiol Biomarkers Prev,2014,23(5):700-713.
[2]Xing X,Tang YB,Yuan G,et al.The prognostic value of E-cadherin in gastric cancer:a meta-analysis[J].Int J Cancer,2013,132(11):2589-2596.
[3]Pasquier J,Abu-Kaoud N,Al Thani H,et al.Epithelial to mesenchymal transition in a clinical perspective[J/OL].J Oncol,2015,2015:792182-792182.
[4]Bruner HC,Derksen PWB.Loss of E-Cadherin-dependent cell-cell adhesion and the development and progression of cancer[J].Cold Spring Harb Perspect Biol,2018,10(3):a029330-a029330.
[5]Capaldo CT,Farkas AE,Nusrat A.Epithelial adhesive junctions[J].F1000Prime Rep,2014,6:1-1.
[6]Nilsson GM,Akhtar N,Kannius-Janson M,et al.Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition[J].Int J Oncol,2014,45(1):82-94.
[7]Nieto MA,Huang RY,Jackson RA,et al.EMT:2016[J].Cell2016,166(1):21-45.
[8]Steinestel K,Eder S,Schrader AJ,et al.Clinical significance of epithelial-mesenchymal transition[J].Clin Transl Med,2014,3:17-17.
[9]Liu X,Chu KM.E-cadherin and gastric cancer:cause,consequence,and applications[J/OL].Biomed Res Int,2014,2014:637308-637308.
[10]LIN Zhi-ping,DUAN Zhao.Relationship between GLI1 and epithelial-mesenchymal transition in gastric cancer and its clinical study[J].China Modern Medicine,2017,24(29):49-52.[林智平,段炤.GLI1与胃癌上皮间质转换的关系及临床研究[J].中国当代医药,2017,24(29):49-52.]
[11]Torabizadeh Z,Nosrati A,Sajadi Saravi SN,et al.Evaluation of E-cadherin expression in gastric cancer and its correlation with clinicopathologic parameters[J].Int J Hematol Oncol Stem Cell Res,2017,11(2):158-164.
[12]Byler S,Goldgar S,Heerboth S,et al.Genetic and epigenetic aspects of breast cancer progression and therapy[J].Anticancer Res,2014,34(3):1071-1077.
[13]Oliveira C,Sousa S,Pinheiro H,et al.Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression[J].Gastroenterology,2009,136(7):2137-2148.
[14]Hansford S,Kaurah P,Li-Chang H,et al.Hereditary diffuse gastric cancer syndrome:CDH1 mutations and beyond[J].JAMA Oncol,2015,1(1):23-32.
[15]Virani S,Colacino JA,Kim JH,et al.Cancer epigenetics:a brief review[J].ILAR J,2012,53(3-4):359-369.
[16]Zeisberg M,Neilson EG.Biomarkers for epithelial-mesenchymal transitions[J].J Clin Invest,2009,119(6):1429-1437.
[17]Jee YS,Jang TJ,Jung KH.Prostaglandin E(2)and interleukin-1βreduce E-cadherin expression by enhancing Snail expression in gastric cancer cells[J].J Korean Med Sci,2012,27(9):987-992.
[18]Hu Z,Liu X,Tang Z,et al.Possible regulatory role of Snail in NF-κB-mediated changes in E-cadherin in gastric cancer[J].Oncol Rep,2013,29(3):993-1000.
[19]Yabusaki N,Yamada S,Murai T,et al.Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer[J].Mol Clin Oncol,2015,3(2):435-441.
[20]Zhou D,Wei Z,Deng S,et al.SASH1 regulates melanocyte transepithelial migration through a novel Gαs-SASH1-IQ-GAP1-E-Cadherin dependent pathway[J].Cell Signal,2013,25(6):1526-1538.
[21]Murai T,Yamada S,Fuchs BC,et al.Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer[J].J Surg Oncol,2014,109(7):684-689.
[22]Barnes RM,Firulli AB.A twist of insight-the role of Twistfamily bHLH factors in development[J].Int J Dev Biol,2009,53(7):909-924.
[23]Choi YJ,Kim N,Chang H,et al.Helicobacter pylori-induced epithelial-mesenchymal transition,a potential role of gastric cancer initiation and an emergence of stem cells[J].Carcinogenesis,2015,36(5):553-563.
[24]Liu AN,Zhu ZH,Chang SJ,et al.Twist expression associated with the epithelial-mesenchymal transition in gastric cancer[J].Mol Cell Biochem,2012,367(1-2):195-203.
[25]Yang Y,Li X,Du J,et al.Involvement of microRNAsMMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with Helicobacter pylori[J].Exp Cell Res,2018,367(2):196-204.
[26]Yu H,Zeng J,Liang X,et al.Helicobacter pylori promotes epithelial-mesenchymal transition in gastric cancer by downregulating programmed cell death protein 4(PDCD4)[J].PLoS One,2014,9(8):e105306-e105306.
[27]Ma DN,Chai ZT,Zhu XD,et al.MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2[J].JHematol Oncol,2016,9:1-1.
[28]Wong TS,Gao W,Chan JY.Interactions between E-Cadherin and microRNA deregulation in head and neck cancers:the potential interplay[J].Biomed Res Int,2014,2014:126038-126038.
[29]Housman G,Byler S,Heerboth S,et al.Drug resistance in cancer:an overview[J].Cancers(Basel),2014,6(3):1769-1792.
[30]Yoshida K,Yoshitomo-Nakagawa K,Seki N,et al.Cloning expression analysis,and chromosomal localization of BH-protocadherin(PCDH7),a novel member of the cadherin superfamily[J].Genomics,1998,49(3):458-461.
[31]Chen HF,Ma RR,He JY,et al.Protocadherin 7 inhibits cell migration and invasion through E-cadherin in gastric cancer[J].Tumour Biol,2017,39(4):1010428317697551-1010428317697551.
[2]Xing X,Tang YB,Yuan G,et al.The prognostic value of E-cadherin in gastric cancer:a meta-analysis[J].Int J Cancer,2013,132(11):2589-2596.
[3]Pasquier J,Abu-Kaoud N,Al Thani H,et al.Epithelial to mesenchymal transition in a clinical perspective[J/OL].J Oncol,2015,2015:792182-792182.
[4]Bruner HC,Derksen PWB.Loss of E-Cadherin-dependent cell-cell adhesion and the development and progression of cancer[J].Cold Spring Harb Perspect Biol,2018,10(3):a029330-a029330.
[5]Capaldo CT,Farkas AE,Nusrat A.Epithelial adhesive junctions[J].F1000Prime Rep,2014,6:1-1.
[6]Nilsson GM,Akhtar N,Kannius-Janson M,et al.Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition[J].Int J Oncol,2014,45(1):82-94.
[7]Nieto MA,Huang RY,Jackson RA,et al.EMT:2016[J].Cell2016,166(1):21-45.
[8]Steinestel K,Eder S,Schrader AJ,et al.Clinical significance of epithelial-mesenchymal transition[J].Clin Transl Med,2014,3:17-17.
[9]Liu X,Chu KM.E-cadherin and gastric cancer:cause,consequence,and applications[J/OL].Biomed Res Int,2014,2014:637308-637308.
[10]LIN Zhi-ping,DUAN Zhao.Relationship between GLI1 and epithelial-mesenchymal transition in gastric cancer and its clinical study[J].China Modern Medicine,2017,24(29):49-52.[林智平,段炤.GLI1与胃癌上皮间质转换的关系及临床研究[J].中国当代医药,2017,24(29):49-52.]
[11]Torabizadeh Z,Nosrati A,Sajadi Saravi SN,et al.Evaluation of E-cadherin expression in gastric cancer and its correlation with clinicopathologic parameters[J].Int J Hematol Oncol Stem Cell Res,2017,11(2):158-164.
[12]Byler S,Goldgar S,Heerboth S,et al.Genetic and epigenetic aspects of breast cancer progression and therapy[J].Anticancer Res,2014,34(3):1071-1077.
[13]Oliveira C,Sousa S,Pinheiro H,et al.Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression[J].Gastroenterology,2009,136(7):2137-2148.
[14]Hansford S,Kaurah P,Li-Chang H,et al.Hereditary diffuse gastric cancer syndrome:CDH1 mutations and beyond[J].JAMA Oncol,2015,1(1):23-32.
[15]Virani S,Colacino JA,Kim JH,et al.Cancer epigenetics:a brief review[J].ILAR J,2012,53(3-4):359-369.
[16]Zeisberg M,Neilson EG.Biomarkers for epithelial-mesenchymal transitions[J].J Clin Invest,2009,119(6):1429-1437.
[17]Jee YS,Jang TJ,Jung KH.Prostaglandin E(2)and interleukin-1βreduce E-cadherin expression by enhancing Snail expression in gastric cancer cells[J].J Korean Med Sci,2012,27(9):987-992.
[18]Hu Z,Liu X,Tang Z,et al.Possible regulatory role of Snail in NF-κB-mediated changes in E-cadherin in gastric cancer[J].Oncol Rep,2013,29(3):993-1000.
[19]Yabusaki N,Yamada S,Murai T,et al.Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer[J].Mol Clin Oncol,2015,3(2):435-441.
[20]Zhou D,Wei Z,Deng S,et al.SASH1 regulates melanocyte transepithelial migration through a novel Gαs-SASH1-IQ-GAP1-E-Cadherin dependent pathway[J].Cell Signal,2013,25(6):1526-1538.
[21]Murai T,Yamada S,Fuchs BC,et al.Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer[J].J Surg Oncol,2014,109(7):684-689.
[22]Barnes RM,Firulli AB.A twist of insight-the role of Twistfamily bHLH factors in development[J].Int J Dev Biol,2009,53(7):909-924.
[23]Choi YJ,Kim N,Chang H,et al.Helicobacter pylori-induced epithelial-mesenchymal transition,a potential role of gastric cancer initiation and an emergence of stem cells[J].Carcinogenesis,2015,36(5):553-563.
[24]Liu AN,Zhu ZH,Chang SJ,et al.Twist expression associated with the epithelial-mesenchymal transition in gastric cancer[J].Mol Cell Biochem,2012,367(1-2):195-203.
[25]Yang Y,Li X,Du J,et al.Involvement of microRNAsMMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with Helicobacter pylori[J].Exp Cell Res,2018,367(2):196-204.
[26]Yu H,Zeng J,Liang X,et al.Helicobacter pylori promotes epithelial-mesenchymal transition in gastric cancer by downregulating programmed cell death protein 4(PDCD4)[J].PLoS One,2014,9(8):e105306-e105306.
[27]Ma DN,Chai ZT,Zhu XD,et al.MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2[J].JHematol Oncol,2016,9:1-1.
[28]Wong TS,Gao W,Chan JY.Interactions between E-Cadherin and microRNA deregulation in head and neck cancers:the potential interplay[J].Biomed Res Int,2014,2014:126038-126038.
[29]Housman G,Byler S,Heerboth S,et al.Drug resistance in cancer:an overview[J].Cancers(Basel),2014,6(3):1769-1792.
[30]Yoshida K,Yoshitomo-Nakagawa K,Seki N,et al.Cloning expression analysis,and chromosomal localization of BH-protocadherin(PCDH7),a novel member of the cadherin superfamily[J].Genomics,1998,49(3):458-461.
[31]Chen HF,Ma RR,He JY,et al.Protocadherin 7 inhibits cell migration and invasion through E-cadherin in gastric cancer[J].Tumour Biol,2017,39(4):1010428317697551-1010428317697551.